Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection)
It is very uncertain whether adalimumab changes failure to maintain endoscopic remission compared with active comparator (very low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review